← All trials
NCT05918302
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 27, 2023
- Primary completion
- Mar 31, 2028
- Completion date
- Jul 31, 2028
- First posted
- Jun 26, 2023
- Last posted
- Nov 2, 2023
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Grupo Espanol de Tumores Neuroendocrinos (GETNE)Lead sponsor
- Universidad Autonoma de BarcelonaStudy chair
- MFAR Clinical ResearchCollaborator
- Universidad Autonoma de BarcelonaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.